After Viking Therapeutics (VKTX) announced a multi-year manufacturing agreement with CordenPharma to support the commercialization of VK2735, Morgan Stanley said the agreement with a single, “reputable peptide manufacturer” is supportive of “a multibillion dollar market opportunity.” The firm, which views the deal as “a best-case scenario” that removes a key overhang, reiterates an Overweight rating and $105 price target on Viking shares.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VKTX:
- Viking Therapeutics Secures Strategic Manufacturing Agreement, Boosting Investor Confidence and Phase 3 Trial Prospects
- Viking Therapeutics Secures Strategic Manufacturing Agreement with CordenPharma, Boosting Growth Potential and Earning Buy Rating
- B. Riley sees two key positives in Viking manufacturing agreement
- Viking supply pact may hurt takeover prospects, says William Blair
- Strategic Manufacturing Deal Boosts Viking Therapeutics’ Stock Outlook
Questions or Comments about the article? Write to editor@tipranks.com